Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,108 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,662 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07657416 | NK521 in the Treatment of Advanced Solid Tumors | not yet recruiting | Early Phase 1 | 18 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT03541720 | 18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma | active not recruiting | Early Phase 1 | 13 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06636175 | 64Cu-LLP2A for Imaging Hematologic Malignancies | recruiting | Early Phase 1 | 42 | Washington University School of MedicineOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05386576 | A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | active not recruiting | Early Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07648823 | Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma | recruiting | Early Phase 1 | 5 | Beijing Tiantan HospitalOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07649928 | A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer | recruiting | Early Phase 1 | 24 | Ruijin HospitalOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT01098955 | Smoking Cessation Treatment for Head & Neck Cancer Patients | active not recruiting | Early Phase 1 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04048278 | Lidocaine Infusion in Pancreatic Cancer | recruiting | Early Phase 1 | 46 | University of Illinois at ChicagoOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05704283 | 3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer | recruiting | Early Phase 1 | 55 | Mayo ClinicOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04494113 | Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy | active not recruiting | Early Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07318389 | ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | not yet recruiting | Early Phase 1 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07608848 | First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer(DOTA-STR-17126) | recruiting | Early Phase 1 | 20 | Integrated Haematology and Oncology NetworkOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07628595 | Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma | not yet recruiting | Early Phase 1 | 19 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07639970 | Evaluation of [⁶⁸Ga/¹⁷⁷Lu]HT547: Safety, Biodistribution, and Dosimetry in Solid Tumors | not yet recruiting | Early Phase 1 | 20 | Hua PangOTHER | 0 | Jun 10, 2026 | clinicaltrials |
| NCT03422731 | Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy | active not recruiting | Early Phase 1 | 82 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04510311 | Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors | completed | Early Phase 1 | 32 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05045066 | Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients | recruiting | Early Phase 1 | 220 | Mayo ClinicOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05245786 | An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer | active not recruiting | Early Phase 1 | 14 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07631299 | Nebulized AER101 in Pre-op NSCLC(AER101) | not yet recruiting | Early Phase 1 | 5 | University of OklahomaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06643221 | Exercise as an Immune Adjuvant for Allogeneic Cell Therapies(Allo-X) | recruiting | Early Phase 1 | 200 | University of ArizonaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07286318 | A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients | recruiting | Early Phase 1 | 20 | Marissa LoblOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05651178 | Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients | active not recruiting | Early Phase 1 | 10 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07626476 | Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis | recruiting | Early Phase 1 | 30 | Beijing Boren HospitalOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT02676050 | Visualising c-MET and Activated Neutrophils in Lung Cancer(DUAL) | terminated | Early Phase 1 | 5 | University of EdinburghOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03964506 | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant | recruiting | Early Phase 1 | 24 | Omar AljitawiOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07439120 | Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors | recruiting | Early Phase 1 | 10 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05477823 | Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer | active not recruiting | Early Phase 1 | 30 | University of Wisconsin, MadisonOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05515978 | Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients(PragMet) | recruiting | Early Phase 1 | 100 | University of Colorado, DenverOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07621471 | IL-15 Enhanced NK Cell Therapy for Solid Tumors | not yet recruiting | Early Phase 1 | 12 | Genovn Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT02210117 | Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery | active not recruiting | Early Phase 1 | 104 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04139304 | A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | recruiting | Early Phase 1 | 15 | AIDS Malignancy ConsortiumNETWORK | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04016818 | Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution | withdrawn | Early Phase 1 | 0 | Stanford UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04211259 | Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization | recruiting | Early Phase 1 | 70 | Rutgers, The State University of New JerseyOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06122896 | Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals | recruiting | Early Phase 1 | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06831526 | Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma | recruiting | Early Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07123662 | γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant | withdrawn | Early Phase 1 | 0 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 0 | May 28, 2026 | clinicaltrials |
| NCT04648904 | Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer | active not recruiting | Early Phase 1 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06308913 | Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma | active not recruiting | Early Phase 1 | 10 | University of Wisconsin, MadisonOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06937567 | CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT04634227 | Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot) | active not recruiting | Early Phase 1 | 30 | University of IowaOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04975217 | Fecal Microbial Transplants for the Treatment of Pancreatic Cancer | suspended | Early Phase 1 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05365893 | PHL Treatment in Pancreatic Cancer | active not recruiting | Early Phase 1 | 20 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05498792 | Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma | recruiting | Early Phase 1 | 12 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07240857 | A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer | enrolling by invitation | Early Phase 1 | 18 | Zhejiang UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03594630 | Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer | recruiting | Early Phase 1 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04219904 | PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer | active not recruiting | Early Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04488224 | Nano-X Image Guidance: CBCT With Gravity-induced Motion(Nano-X IG) | withdrawn | Early Phase 1 | 0 | University of SydneyOTHER | 0 | May 19, 2026 | clinicaltrials |
| NCT07597759 | Phase IIT Trial of SNA009 | completed | Early Phase 1 | 12 | SmartNuclide BiopharmaINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07597772 | Preliminary Trial of SNA014 for Pancreatic Cancer | recruiting | Early Phase 1 | 12 | SmartNuclide BiopharmaINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT04187703 | 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies | recruiting | Early Phase 1 | 20 | Benjamin TomlinsonOTHER | 1 | May 18, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 18, 2026source: clinicaltrials